The Efficacy and Tolerability of Nebivolol in Hypertensive African American Patients

Authors

  • Elijah Saunders MD,

    1. From the Section of Hypertension, University of Maryland School of Medicine, Baltimore, MD;1New Orleans Center for Clinical Research, New Orleans, LA;2Tulane University, New Orleans, LA;3 and Mylan Pharmaceuticals, Morgantown, WV4
    Search for more papers by this author
  • 1 William B. Smith MD,

    1. From the Section of Hypertension, University of Maryland School of Medicine, Baltimore, MD;1New Orleans Center for Clinical Research, New Orleans, LA;2Tulane University, New Orleans, LA;3 and Mylan Pharmaceuticals, Morgantown, WV4
    Search for more papers by this author
  • 2 Karen B. DeSalvo MD,

    1. From the Section of Hypertension, University of Maryland School of Medicine, Baltimore, MD;1New Orleans Center for Clinical Research, New Orleans, LA;2Tulane University, New Orleans, LA;3 and Mylan Pharmaceuticals, Morgantown, WV4
    Search for more papers by this author
  • and 3 Will A. Sullivan MD 4

    1. From the Section of Hypertension, University of Maryland School of Medicine, Baltimore, MD;1New Orleans Center for Clinical Research, New Orleans, LA;2Tulane University, New Orleans, LA;3 and Mylan Pharmaceuticals, Morgantown, WV4
    Search for more papers by this author

Elijah Saunders, MD, Section of Hypertension, University of Maryland School of Medicine, University of Maryland Professional Building, 419 West Redwood Street, Suite 620, Baltimore, MD 21201
E-mail: esaunder@medicine.umaryland.edu

Abstract

Hypertensive African Americans often respond poorly to β-blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if β-blockers with vasodilating effects are used. This 12-week, multi-center, double-blind, randomized placebo-controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating β1-blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] ≥95 mm Hg and ≤109 mm Hg). The primary efficacy end point was the baseline-adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP (P≤.004) at all doses of 5 mg and higher and sitting systolic blood pressure (P≤.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well-tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.

Ancillary